Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Autor:	Tamura, Kenji, Tsurutani, Junji, Takahashi, Shunji, Iwata, Hiroji, Krop, Ian E, Redfern, Charles, Sagara, Yasuaki, Doi, Toshihiko, Park, Haeseong, Murthy, Rashmi K, Redman, Rebecca A, Jikoh, Takahiro, Lee, Caleb, Sugihara, Masahiro, Shahidi, Javad, Yver, Antoine, Modi, Shanu
Zdroj:	In The Lancet Oncology June 2019 20(6):816-826
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu